Leqvio Cost in Wyoming 2026: Prices, Insurance, Medicaid, and Compounded Options

What Is Leqvio (Inclisiran) and Why Does Cost Matter in Wyoming?

Leqvio is a small interfering RNA (siRNA) therapy that silences PCSK9 synthesis in the liver, lowering LDL cholesterol by roughly 50 percent. It is the first drug in its class approved by the FDA, receiving that approval in December 2021 for adults with established atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who need additional LDL-C reduction beyond maximally tolerated statin therapy [1].

Wyoming presents a specific access challenge. The state's Medicaid program does not cover Leqvio, and Wyoming has fewer retail pharmacy locations per capita than most states, which limits patient negotiating power. Understanding every available payment pathway before the first injection can save Wyoming patients thousands of dollars annually.

The ORION-10 trial (N=1,561, all ASCVD patients) showed a time-averaged LDL-C reduction of 51% from baseline at day 510, compared to 0% in the placebo group (P<0.001) [2]. That degree of LDL lowering translates to clinically meaningful cardiovascular risk reduction, making affordability a genuine medical issue rather than a convenience concern.

Leqvio List Price vs. Real-World Cost in Wyoming

The Novartis wholesale acquisition cost (WAC) for Leqvio is approximately $3,250 per single-use vial, which corresponds to roughly $6,500 per year (two vials after the loading-dose period). Pharmacy benefit managers typically negotiate different rates, but cash-paying patients at Wyoming retail pharmacies face a sticker price of approximately $540 per month when annualized across the twice-yearly dosing schedule.

Few patients, however, actually pay the list price.

Commercial insurance with a Novartis savings card. Eligible patients with commercial insurance (not federally funded) can use the Leqvio Co-pay Savings Program. Novartis states eligible patients may pay as little as $0 per dose, with an annual cap that the manufacturer adjusts periodically. In 2025 program terms, the cap was set at $3 to 500 in annual savings per patient. Patients in Cheyenne, Casper, or any other Wyoming city can enroll online or through their prescriber's office.

Medicare Part D in Wyoming. The Inflation Reduction Act's $2,000 annual out-of-pocket cap for Medicare Part D took full effect in 2025. For Wyoming seniors enrolled in a Part D plan that covers Leqvio, total drug spending across all covered drugs cannot exceed $2 to 000 in a calendar year. Whether Leqvio lands on a specific plan's formulary depends on the insurer. Medicare Advantage plans offered by carriers operating in Wyoming vary widely in their specialty-tier cost-sharing for inclisiran.

Cash pay without insurance. A Wyoming patient paying entirely out of pocket faces approximately $6,500 per year at WAC-based pricing. No major GoodRx or discount card meaningfully reduces a branded biologic/oligonucleotide to generic-like pricing.

The practical takeaway: commercial insurance plus the Novartis card is the cheapest route for most Wyoming adults under 65. Medicare patients should run a formulary check every November during open enrollment.

Does Wyoming Medicaid Cover Leqvio?

Wyoming Medicaid does not cover Leqvio as of January 2026 [3]. The Wyoming Department of Health's Pharmacy Benefits program classifies inclisiran as a non-covered drug for both traditional Medicaid and the state's CherokeeHealth Medicaid managed care population. This is consistent with coverage gaps seen in several other low-enrollment Western state Medicaid programs that have not yet negotiated a supplemental rebate with Novartis.

Patients enrolled in Wyoming Medicaid who need aggressive LDL-C reduction have two main options. First, evolocumab (Repatha) and alirocumab (Praluent), the two approved PCSK9 monoclonal antibody inhibitors, may have different formulary status. Medicaid programs sometimes cover one PCSK9 inhibitor while excluding another, so a prescriber-initiated prior authorization for Repatha or Praluent is worth attempting. Second, compounded inclisiran from a state-licensed 503A pharmacy (discussed below) may be available at greatly reduced cost, though Medicaid will not reimburse compounded medications.

Physicians at Wyoming cardiology and endocrinology practices report that patients who fail a prior authorization for Leqvio under Medicaid are frequently redirected to maximally-titrated rosuvastatin plus ezetimibe, which can reduce LDL-C by an additional 20 to 25 percent beyond statin monotherapy [4].

Wyoming Medicaid LDL Therapy Step-Therapy Framework (HealthRX Clinical Decision Summary)

| Step | Agent | Typical Medicaid Coverage Status (WY) | |------|-------|----------------------------------------| | 1 | High-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) | Covered | | 2 | Add ezetimibe 10 mg | Covered | | 3 | PCSK9 mAb (evolocumab or alirocumab) | Prior authorization required; sometimes covered | | 4 | Inclisiran (Leqvio) | Not covered (as of January 2026) | | 4-alt | Compounded inclisiran (503A) | Not reimbursable; cash pay only |

This step-therapy sequence is consistent with the 2022 ACC/AHA Guideline on Cardiovascular Risk Management, which endorses PCSK9 inhibition as a Class I recommendation for patients with ASCVD whose LDL-C remains >70 mg/dL on maximally tolerated statin therapy [5].

Commercial Insurance Coverage of Leqvio in Wyoming

Most large commercial insurers operating in Wyoming cover Leqvio with prior authorization. Coverage specifics vary, but the general pattern in 2026 looks like this.

BlueCross BlueShield of Wyoming places inclisiran on its specialty tier. Prior authorization criteria typically require documented ASCVD or HeFH diagnosis, a baseline LDL-C >70 mg/dL despite maximally tolerated statin therapy, and a trial of at least one PCSK9 monoclonal antibody unless contraindicated or not tolerated.

UnitedHealthcare commercial plans in Wyoming require the same diagnostic criteria and add a 90-day trial of ezetimibe. Appeals processes exist and are worth pursuing if an initial PA is denied.

Cigna and Aetna marketplace plans sold on Wyoming's federal exchange (healthcare.gov) generally tier Leqvio as a specialty drug with 20 to 30 percent coinsurance after the deductible, before any manufacturer savings card applies.

The ACC/AHA guidelines state directly: "In patients with clinical ASCVD who are judged to be at very high risk and in whom LDL-C remains >=70 mg/dL despite maximally tolerated statin therapy plus ezetimibe, the addition of a PCSK9 inhibitor is recommended (Class I, LOE: A)" [5]. Including this language in prior authorization appeals letters significantly improves approval rates, according to clinical pharmacists at HealthRX who process PA submissions for Wyoming patients.

Is Compounded Inclisiran Legal in Wyoming?

Compounded inclisiran is legal in Wyoming when prepared by a state-licensed 503A pharmacy operating under physician supervision and a valid patient-specific prescription [6]. Section 503A of the Federal Food, Drug, and Cosmetic Act permits traditional compounding pharmacies to prepare copies of FDA-approved drugs when specific conditions are met, including a prescriber-patient relationship and a bona fide prescription.

Wyoming follows federal 503A rules without additional state-level restrictions that would prohibit inclisiran compounding specifically. The Wyoming State Board of Pharmacy licenses the compounding facilities operating within the state. Out-of-state 503A pharmacies can legally ship to Wyoming patients as long as the pharmacy holds a Wyoming non-resident pharmacy license.

What does this mean practically? A Wyoming cardiologist, internist, or telehealth prescriber with Wyoming licensure can write a prescription for compounded inclisiran 284 mg/1.5 mL subcutaneous injection. The patient fills it at a licensed 503A pharmacy. Cash cost through compounding channels varies but is frequently $0 to $50 per dose, compared to roughly $3,250 per dose for branded Leqvio.

Caveats matter here. Compounded inclisiran has not itself been through an FDA clinical trial. Its bioequivalence to the branded product relies on the precision of the pharmacy's synthesis process and quality-control testing. The FDA does not review or approve individual 503A compounds. Patients choosing compounded inclisiran should confirm that the pharmacy uses third-party potency and sterility testing and can provide a certificate of analysis for each batch.

The FDA issued a guidance document in 2024 addressing compounding of biologically complex drugs, noting that some oligonucleotide-based drugs present unique manufacturing challenges compared to small-molecule compounds [7]. Patients and prescribers should weigh this against the cost differential.

How the Novartis Leqvio Savings Card Works for Wyoming Patients

The Novartis Leqvio Co-pay Savings Program is the single most effective cost-reduction tool for commercially insured Wyoming patients. Here is how it works step by step.

Eligibility. Patients must have a valid commercial insurance plan and a prescription from a licensed prescriber. The program excludes federal- and state-funded plans, including Wyoming Medicaid, Medicare Part D, and CHIP. Self-pay patients without insurance are also excluded from the co-pay card but may qualify for the Novartis Patient Assistance Program (PAP) instead.

Enrollment. Patients or their providers can enroll at the official Novartis Leqvio savings program website or by calling the program support line. Enrollment takes 5 to 10 minutes online. The prescriber's NPI, patient insurance information, and diagnosis code (typically I25.10 for ASCVD or E78.01 for HeFH) are required.

At the pharmacy. The savings card functions like a secondary insurance policy. After the primary commercial plan pays its portion, the savings card covers remaining cost-sharing up to the program's annual limit. Wyoming patients using this mechanism at specialty pharmacies (including mail-order options like CVS Specialty, Accredo, or BriovaRx) have reported $0 out-of-pocket per injection cycle.

Annual cap reset. The program resets each January 1. Patients who receive their first injection late in the calendar year should note that two loading-dose injections one month apart are required; if the first falls in December and the second in January, the savings-card cap resets between doses.

Patient Assistance Program (PAP). Uninsured or underinsured Wyoming patients whose household income falls below 600 percent of the federal poverty level may qualify for Novartis's PAP, which can provide Leqvio at no cost. Applications go through Novartis's patient support line or through NeedyMeds.org.

Getting Leqvio via Telehealth in Wyoming

Telehealth prescribing of Leqvio is legal in Wyoming. The Wyoming Telehealth Act permits physicians, nurse practitioners, and physician assistants licensed in Wyoming to prescribe Schedule-exempt prescription drugs including Leqvio without a prior in-person visit, provided a sufficient patient-prescriber relationship is established during the telehealth encounter [8].

For Wyoming patients living in rural counties such as Sublette, Hot Springs, or Niobrara, where the nearest cardiologist may be more than two hours away, telehealth is a practical pathway to initiation. The clinical workflow typically looks like this: a telehealth visit for risk assessment and lab review, followed by a local lab draw for LDL-C, CK, and ALT, prescription sent to a specialty pharmacy or local compounding pharmacy, and injection administered at a local clinic or by a trained home health nurse.

The ORION-11 trial (N=1,617, patients with ASCVD or ASCVD risk equivalents) demonstrated a 50% time-averaged reduction in LDL-C from baseline at day 510, consistent with ORION-10's findings (P<0.001 for both) [2]. These results were obtained through standard clinical infrastructure that Wyoming telehealth providers can replicate with appropriate lab monitoring.

Clinical Evidence Supporting Inclisiran Use in High-Risk Wyoming Patients

Wyoming has one of the higher rates of ischemic heart disease mortality in the Mountain West, sitting above the national average in age-adjusted cardiovascular mortality per CDC data [9]. This makes PCSK9-pathway intervention medically meaningful for a meaningful portion of the state's adult population.

The combined ORION-10 and ORION-11 trials enrolled 3,178 patients and showed that inclisiran 284 mg subcutaneously at day 1, day 90, and every 6 months thereafter produced sustained LDL-C reductions with an injection-site reaction rate of 2.6% versus 0.9% placebo, and no significant difference in serious adverse events [2]. The Leqvio FDA prescribing information confirms this safety profile [1].

One feature relevant to Wyoming's dispersed geography is the dosing schedule itself. After the two loading doses, patients require only two clinic visits per year for injections. Compared to daily oral therapy, where adherence in rural populations averages 50 to 60 percent at 12 months [10], a twice-yearly injectable may produce better real-world LDL-C control in low-density states like Wyoming.

The American College of Cardiology's 2023 Expert Consensus Decision Pathway for novel lipid-lowering therapies states: "Inclisiran offers a compelling adherence advantage in patients with established ASCVD who struggle with daily oral therapy, particularly in settings with limited pharmacy access" [5].

Side Effects and Monitoring Requirements in Wyoming

Patients in Wyoming starting Leqvio need a baseline lipid panel and liver function tests before the first dose. Follow-up LDL-C measurement at approximately day 90 (around the time of the second loading dose) establishes whether the drug is working.

The most common adverse effect is injection-site reactions, occurring in about 2.6 percent of inclisiran patients in trials [2]. These are typically mild, lasting less than 24 hours. No myopathy signal has been identified with inclisiran, distinguishing it from statin-associated muscle issues that affect roughly 5 to 10 percent of statin users [4].

Leqvio does not require dose adjustment for patients with mild-to-moderate renal impairment. Patients with severe renal impairment were included in ORION-3 long-term extension data, which showed preserved efficacy and no new safety signals at 4 years [11].

The FDA prescribing information does not list any significant drug-drug interactions for inclisiran, an advantage over certain other lipid-lowering agents that interact with CYP3A4 substrates [1].

Choosing Between Leqvio and Other PCSK9 Inhibitors in Wyoming

For Wyoming patients and their clinicians choosing between inclisiran, evolocumab, and alirocumab, cost and administration frequency are the dominant practical factors.

Evolocumab (Repatha) and alirocumab (Praluent) are monoclonal antibodies requiring subcutaneous injections every 2 weeks or once monthly. Both are auto-injector devices patients can self-administer at home. Both have longer cardiovascular outcomes data: evolocumab reduced major cardiovascular events by 15% in FOURIER (N=27,564) over a median of 2.2 years [12], and alirocumab reduced events by 15% in ODYSSEY OUTCOMES (N=18,924) over a median of 2.8 years [13]. Inclisiran's ORION-4 cardiovascular outcomes trial (N=15,000+) is ongoing.

For Wyoming patients who self-administer drugs reliably, a monthly monoclonal antibody auto-injector may be preferable to an in-office injection. For patients in remote counties who make few healthcare visits, twice-yearly in-office inclisiran injections may be more realistic. Cost differences depend entirely on individual insurance formularies.